|
Jun 23, 2020
|
Catalyst Pharmaceuticals Appoints Jeffrey Del Carmen as Chief Commercial Officer
- Pete Curry has been Promoted to Vice President of Sales - Maria Pandolfo has been Promoted to Vice President of Patient Services CORAL GABLES, Fla. , June 23, 2020 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on
|
|
|
Jun 01, 2020
|
Catalyst Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference
CORAL GABLES, Fla. , June 01, 2020 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological
|
|
|
May 11, 2020
|
Catalyst Pharmaceuticals Announces First Quarter 2020 Financial Results and Provides Corporate Update
Firdapse® Q1 2020 Net Revenues of $29.1 Million First Quarter 2020 GAAP Net Income of $10.4 Million Catalyst Withdraws Previous 2020 Revenue Guidance Due to COVID-19 Uncertainties Catalyst to Host Quarterly Conference Call at 8:30 AM ET Tomorrow CORAL GABLES, Fla.
|
|
|
May 04, 2020
|
Catalyst Pharmaceuticals to Hold First Quarter 2020 Financial Results and Corporate Update Conference Call and Webcast on Tuesday, May 12th, 2020
CORAL GABLES, Fla. , May 04, 2020 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological
|
|
|
Apr 08, 2020
|
Catalyst Pharmaceuticals Provides Update on Impact of COVID-19 Pandemic on its Business Activities
Safety of personnel, patients and healthcare providers remains our top priority Drug supply remains well-stocked with patients having access to uninterrupted supply of Firdapse® (amifampridine) 10mg Catalyst partners with First Responders Children’s Foundation to support COVID-19 EMERGENCY
|
|
|
Mar 16, 2020
|
Catalyst Pharmaceuticals Reports Fourth Quarter and Year-End 2019 Financial Results and Provides Corporate Update
-Firdapse ® Q4 Net Revenues of $30 Million , FY 19 Net Revenues of $102 Million -GAAP Net Income of $32 Million for Fiscal Year 2019 -Catalyst Reiterates Net Revenue Guidance in the Range of $135 Million to $155 Million for FY 2020 -Firdapse Supply Chain in Solid Position-Significant Safety Stock
|
|
|
Mar 10, 2020
|
Catalyst Pharmaceuticals to Hold Fourth Quarter and Year-End Financial Results and Corporate Update Conference Call and Webcast on Tuesday, March 17th, 2020
CORAL GABLES, Fla. , March 10, 2020 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological
|
|
|
Feb 27, 2020
|
Catalyst Pharmaceuticals Announces Support of Rare Disease Day 2020
CORAL GABLES, Fla. , Feb. 27, 2020 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological
|
|
|
Feb 26, 2020
|
Catalyst Pharmaceuticals to Present at the Cowen 40th Annual Health Care Conference
CORAL GABLES, Fla. , Feb. 26, 2020 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological
|
|
|
Feb 06, 2020
|
Catalyst Pharmaceuticals to Present at the 22nd Annual BIO CEO & Investor Conference
CORAL GABLES, Fla. , Feb. 06, 2020 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological
|
|
